Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Sea Limited — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Sea Limited trades at $96.63 (market cap $58.38B). The key difference: Sea Limited is far larger — about 6.6× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Sea Limited for 103 Days on average.
| KYMR | SE | |
|---|---|---|
Market Cap | $8.88B | $58.38B |
Volume | 1,028,790 | 3,918,232 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $165.70 |
52-Week Low | $55.80 | $78.16 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $8.27B | $53.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sea Limited (SE) trades at $95.93, showing minimal daily movement (+0.05%). The stock faces bearish technical signals despite strong fundamentals, with revenue growing from $12.4B in 2022 to $22.9B in 2025 and net income turning positive at $1.58B. Recent earnings show mixed results with Q4 2025 missing expectations but subsequent quarters beating estimates. Analyst sentiment remains strongly bullish with a $153.67 consensus target, representing 60% upside potential from current levels.
The investment case hinges on continued e-commerce and fintech growth execution against competitive pressures. Key risks include margin compression concerns and insider selling activity. With positive cash flow generation established and strong institutional support, the stock presents a compelling growth opportunity despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
